The results of EUROPE (efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease) and the HOPE (Heart Out- comes Prevention Evaluation) trials contribute to the decreased risk of myocardial infarction with ACE inhibitors. This evidence concerns the gene ACE and myocardial infarction.